Sebum Control Composition for Sustained Sebocyte Lipid Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing cosmetic treatments for excessive sebum production, such as oily skin and acne, do not address the underlying causes and often exacerbate the condition with prolonged use.

Innovation Solution

A composition comprising oleanolic acid combined with compounds like ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, and tyramine, optionally with plant extracts from Fragaria vesca or Rubus idaeus, reduces lipid production in sebocytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If cosmetic treatments such as powders and astringents are used to absorb excess sebum, then immediate relief from oiliness is achieved, but the underlying cause of excessive lipid production is not addressed and results are not sustainable

Engineering Contradiction:

Improveimmediate relief from oilinessVSAvoidsustainability of results

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent extracts and targets the root cause of excessive sebum production by inhibiting lipid synthesis enzymes (FAS, SCAP, SCD) within sebocytes, rather than merely masking symptoms on the skin surface. This extraction of the problematic process (lipid production) leads to sustainable reduction in sebum output.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The composition acts preliminarily by preventing excessive lipid production before it occurs through enzyme inhibition, rather than reacting to or masking the symptoms after they manifest. This preliminary intervention at the cellular level ensures long-term sustainability of results.

Inventive Principle:

Principle #10Preliminary action

2Quantity of substance

If astringents and cleaning agents are used to reduce sebum, then skin oiliness is reduced temporarily, but prolonged use may exacerbate the condition

Engineering Contradiction:

Improvesebum amountVSAvoidskin barrier damage

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of harsh cleaning agents into a benefit by using a gentle, non-irritating composition that reduces sebum through biochemical inhibition rather than mechanical removal. This approach maintains skin barrier integrity while achieving sebum reduction.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The invention changes the mechanism from physical removal (astringents/cleaning agents) to biochemical modulation (enzyme inhibition). This parameter change in the mode of action allows for sustained sebum reduction without the harmful side effects of prolonged use of traditional agents.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If known lipid-reducing methods are used, then some sebum reduction is achieved, but visible results are limited over extended periods

Engineering Contradiction:

Improvesebum reduction efficacyVSAvoidduration of visible results

Core Design Contradiction:

ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent employs a composite formulation containing multiple active compounds (oleanolic acid, ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, protocatechuic acid, and tyramine) that work synergistically to inhibit lipid synthesis enzymes. This composite approach enhances both the efficacy and duration of sebum reduction compared to single-agent treatments.

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20250360146A1Compositions for sebum control

Publication Date: 2025.11.27 DYSON OPERATIONS PTE LTD

AI summary

The invention provides a composition comprising oleanolic acid and the salts, prodrug and solvates thereof; and one or more compounds selected from the following group: ellagic acid, adenine, betaine, choline, miquelianin, p-coumaric acid, pipecolic acid, protocatechuic acid and tyramine, and the salts, prodrugs and solvates thereof. Such a composition is for use in reducing lipid levels in sebocytes, and the composition may find use in treating acne vulgaris and rosacea.